GACP Certification Awarded to Internationally-Based Extracts Company
A multinational, pharmaceutical-grade medical cannabis and hemp extracts company, Clever Leaves, was recently granted a good agricultural and collecting practices (GACP) certification by the Control Union Medical Cannabis Standard (CUMCS) for meeting their guidelines for consistency and quality in the cultivation and harvest of medicinal cannabis.
A multinational, pharmaceutical-grade medical cannabis and hemp extracts company, Clever Leaves, was recently granted a good agricultural and collecting practices (GACP) certification by the Control Union Medical Cannabis Standard (CUMCS) for meeting their guidelines for consistency and quality in the cultivation and harvest of medicinal cannabis (1).
CUMCS’s standards offer general technical guidance for obtaining high-quality medicinal plant materials for the sustainable production of herbal items categorized as medicinal products. With the GACP certification, Clever Leaves is able to show that they operate under CUMCS procedures, cultivating crops that are free of heavy metals and agrochemicals as well as protocols for biodiversity safety in pharmaceutical manufacturing.
In Clever Leaves press release the company stated (1): “The CUMCS certification standard is based on GACP guidelines of The World Health Organization (WHO), the GACP Guidelines of the European Medicines Agency, Guidelines of the Dutch Government for Cannabis for Medical Use, and the International Standard for Good Agriculture Practice.”
“GACP certification reflects Clever Leaves’ ability to produce pharmaceutical-grade cannabis as well as our adherence to stringent operational standards,” said Kyle Detwiler, the CEO of Clever Leaves (1). “Achieving internationally-recognized quality guidelines will enable us to bring value at every touch point of the supply chain.”
With the GACP certification, Clever Leaves will be able to export pharmaceutical-grade cannabis products to international markets.
References:
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
